Medicinova financials
$1.92−8.57%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $458.4K | $187.0K | $151.7K | $123.3K | $134.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.0M |
| Gross profit | $458.4K | $187.0K | $151.7K | $123.3K | $134.6K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | 100.0% |
| Operating income | -$2.5M | -$2.8M | -$3.1M | -$3.4M | -$3.6M | -$3.2M | -$3.2M | -$3.3M | -$3.0M | -$3.1M | -$2.5M | -$1.1M |
| Net income | -$2.3M | -$2.6M | -$2.8M | -$3.1M | -$3.3M | -$2.9M | -$2.8M | -$2.9M | -$2.6M | -$2.8M | -$2.1M | -$723.1K |
| Net margin | −504.8% | −1383.1% | −1846.8% | −2473.6% | −2437.7% | — | — | — | — | — | — | −72.3% |
| Diluted EPS | $-0.05 | $-0.05 | $-0.06 | $-0.06 | $-0.07 | $-0.06 | $-0.06 | $-0.06 | $-0.05 | $-0.06 | $-0.04 | $-0.01 |
| EBITDA | -$2.5M | -$2.8M | -$3.1M | -$3.4M | -$3.6M | -$3.2M | -$3.2M | -$3.3M | -$3.0M | -$3.1M | -$2.5M | -$1.1M |
| Operating cash flow | -$1.9M | -$3.5M | -$2.0M | -$1.7M | -$2.3M | -$3.8M | -$1.9M | -$2.0M | -$2.8M | -$3.9M | -$499.1K | -$1.4M |
| Free cash flow | -$1.9M | -$3.5M | -$2.0M | -$1.7M | -$2.3M | -$3.8M | -$1.9M | -$2.0M | -$2.8M | -$3.9M | -$499.1K | -$1.4M |
| Diluted shares | 49.2M | 49.2M | 49.1M | 49.0M | 49.0M | 49.0M | 49.0M | 49.0M | 49.0M | 49.0M | 49.0M | 49.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $25.4M | $27.3M | $30.8M | $32.6M | $34.3M | $36.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $40.4M | $42.7M | $45.6M | $47.6M | $49.8M | $52.4M |
| Total liabilities | $3.2M | $3.3M | $4.0M | $3.6M | $3.0M | $2.5M |
| Shareholders' equity | $37.3M | $39.4M | $41.6M | $44.0M | $46.9M | $49.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology